Ticker LaunchReverse merger · Completed · NGNE
Neurogene Inc.
Reverse merger with Neoleukin Therapeutics, Inc.
Neurogene Inc. merged into Neoleukin Therapeutics, Inc., a Nasdaq-listed biotechnology company, in a reverse merger that takes the private company public. The deal was announced on Jul 18, 2023 and closed on Dec 19, 2023. The combined company trades as Neurogene Inc. (NGNE) on Nasdaq.
Neurogene Inc. is a clinical-stage company developing genetic medicines for complex neurological diseases, with lead gene therapy candidate NGN-401 in a Phase 1/2 trial for female pediatric patients with Rett syndrome.
- Status
- Completed
- Private company
- Neurogene Inc.
- Public company
- Neoleukin Therapeutics, Inc.
- Public company business before
- Nasdaq-listed biotechnology company
- Announced
- Jul 18, 2023
- Closed
- Dec 19, 2023
- Combined company
- Neurogene Inc. (NGNE)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Dec 19, 2023
- Closing press release / exhibit
- Announcement 8-K Jul 18, 2023
- Announcement press release
- All filings on EDGAR CIK 1404644
Other completed reverse mergers
- H2 Energy Group Inc. (H2EG)into Victory Oilfield Tech, Inc. · Jan 1, 2024
- Two Trees Beverage Companyinto MDwerks, Inc. · Dec 8, 2023
- Cartesian Therapeutics, Inc.into Selecta Biosciences, Inc. · Nov 13, 2023
- Korro Bio, Inc.into Frequency Therapeutics, Inc. · Nov 3, 2023
- Beijing Continent Pharmaceuticals Co., Ltd. (via GNI Group)into Catalyst Biosciences, Inc. · Oct 30, 2023
- Tourmaline Bio, Inc.into Talaris Therapeutics, Inc. · Oct 19, 2023